

Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery

NCT03841058

Status	RECRUITING
Phase	Phase 2
Sponsor	Hospital for Special Surgery, New York
Enrollment	96 participants

Key Eligibility Criteria

Inclusion (3)

- Postmenopausal women (defined as >12 months since last menstrual cycle) OR men
- Age of 50 years or older
- Requiring posterolateral lumbar spine fusion surgery (L1-2; L2-3; L3-4; L4-5, L5-S1) with single or multi-level fusion for degenerative conditions of the lumbar spine (including lumbar degenerative disk disease, severe instability, high grade spondylolisthesis, deformity, degenerative scoliosis, pseudoarthrosis, and spinal stenosis) under the care of spine surgeons at the Hospital for Special Surgery.

Exclusion (14)

- Hypersensitivity to abaloparatide
- Patients with increased risk of osteosarcoma: Paget's disease, prior radiation therapy
- Patients with active hypercalcemia or current diagnosis of hyperparathyroidism
- History of multiple renal calculi or renal calculus within 2 years
- Unexplained elevations in alkaline phosphatase
- ... and 9 more (see full listing online)

Locations (1 total)

Hospital for Special Surgery, New York, New York, United States